Volume | 615,980 |
|
|||||
News | - | ||||||
Day High | 39.10 | Low High |
|||||
Day Low | 36.92 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Rhythm Pharmaceuticals Inc | RYTM | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
37.79 | 36.92 | 39.10 | 38.01 | 38.11 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
8,959 | 615,980 | $ 37.69 | $ 23,218,167 | - | 15.5001 - 52.57 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:23:22 | 17 | $ 39.00 | USD |
Rhythm Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.29B | 60.14M | - | 77.43M | -184.68M | -3.07 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Rhythm Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RYTM Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 42.01 | 42.09 | 36.92 | 39.30 | 586,186 | -4.00 | -9.52% |
1 Month | 40.67 | 43.68 | 36.92 | 40.78 | 527,247 | -2.66 | -6.54% |
3 Months | 44.68 | 52.57 | 36.92 | 43.47 | 589,570 | -6.67 | -14.93% |
6 Months | 23.41 | 52.57 | 21.34 | 40.05 | 668,876 | 14.60 | 62.37% |
1 Year | 20.69 | 52.57 | 15.5001 | 30.05 | 685,803 | 17.32 | 83.71% |
3 Years | 19.44 | 52.57 | 3.04 | 19.86 | 755,080 | 18.57 | 95.52% |
5 Years | 26.03 | 52.57 | 3.04 | 20.69 | 566,781 | 11.98 | 46.02% |
Rhythm Pharmaceuticals Description
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. |